In November 2017, Emerald Health Therapeutics, Inc. acquired 1,666,6667 units of Avricore Health Inc. and in April, 2018 Avricore entered into a supply and distribution agreement with an affiliate of Emerald Health Therapeutics, Inc. pursuant to which Avricore was granted rights to sell and distribute certain proprietary endocannabinoid products in Canada to licensed pharmacies.

As part of the agreement, we will offer:

Endocannabinoid Nutraceuticals - Summer 2019

A multi-award winning, condition specific product line that offers advanced support for the endocannabinoid system. Avricore was granted rights to sell and distribute proprietary endocannabinoid-supporting products in Canada to licensed pharmacies. Working closely with Emerald, focusing on generating information and products most relevant to the pharmacy channel.

Medical Cannabis - 2020

Strategic partnership with Emerald enables Avricore to compete in the emerging medical cannabis sector. Avricore will publish medical cannabis educational courses for pharmacists on its Corozon Platform. Potential to distribute medical cannabis to pharmacies when that avenue of sales is enabled.